TY - JOUR
T1 - Serum levels of soluble CD163 correlate with the inflammatory process in coeliac disease
AU - Daly, A.
AU - Walsh, C.
AU - Feighery, C.
AU - O'Shea, U.
AU - Jackson, J.
AU - Whelan, A.
PY - 2006/8
Y1 - 2006/8
N2 - Backgound: In coeliac disease, following the introduction of a gluten-free diet, monitoring mucosal disease activity requires repeated small intestinal biopsies. If a test measuring a circulating inflammatory marker was available, this would be clinically valuable. Aim: To determine if levels of soluble CD163, a scavenger receptor shed by tissue macrophages, correlated with the inflammatory lesion in coeliac disease. Methods: Serum samples were collected from 131 patients with untreated coeliac disease, 40 patients with treated coeliac disease, 92 non-coeliac disease control subjects and 131 healthy controls. A capture enzyme linked immunosorbance assay was established to measure levels of soluble CD163 in sera. The extent of the histological lesion in coeliac biopsies was assessed using a Marsh grading system. Results: Levels of CD163 in untreated coeliac subjects were significantly elevated when compared with the treated coeliac patients, the disease control group and the healthy control subjects (P < 0.0001 in each instance). Moreover, coeliac patients with the most marked histological lesion (Marsh 3) had significantly higher levels of soluble CD163 than patients with Marsh grade 2 lesions (P < 0.0004), with grade 1 lesions (P < 0.0001) and grade 0 lesions (P < 0.0001). Conclusions: Measurement of soluble CD163 may be a useful method of monitoring the inflammatory lesion in coeliac disease.
AB - Backgound: In coeliac disease, following the introduction of a gluten-free diet, monitoring mucosal disease activity requires repeated small intestinal biopsies. If a test measuring a circulating inflammatory marker was available, this would be clinically valuable. Aim: To determine if levels of soluble CD163, a scavenger receptor shed by tissue macrophages, correlated with the inflammatory lesion in coeliac disease. Methods: Serum samples were collected from 131 patients with untreated coeliac disease, 40 patients with treated coeliac disease, 92 non-coeliac disease control subjects and 131 healthy controls. A capture enzyme linked immunosorbance assay was established to measure levels of soluble CD163 in sera. The extent of the histological lesion in coeliac biopsies was assessed using a Marsh grading system. Results: Levels of CD163 in untreated coeliac subjects were significantly elevated when compared with the treated coeliac patients, the disease control group and the healthy control subjects (P < 0.0001 in each instance). Moreover, coeliac patients with the most marked histological lesion (Marsh 3) had significantly higher levels of soluble CD163 than patients with Marsh grade 2 lesions (P < 0.0004), with grade 1 lesions (P < 0.0001) and grade 0 lesions (P < 0.0001). Conclusions: Measurement of soluble CD163 may be a useful method of monitoring the inflammatory lesion in coeliac disease.
UR - http://www.scopus.com/inward/record.url?scp=33745910232&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2036.2006.03012.x
DO - 10.1111/j.1365-2036.2006.03012.x
M3 - Article
C2 - 16886922
AN - SCOPUS:33745910232
SN - 0269-2813
VL - 24
SP - 553
EP - 559
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 3
ER -